Advancements and Acquisitions Fueled Mid-Cap Biotech R&D Spend in 2014, Says Report
April 23, 2015.
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, says research and consulting firm GlobalData. GlobalData's PharmaLeaders: Mid-Cap Biotechnology Benchmark Report states that Regeneron led the way with R&D expenses of $860 million in 2013, with further analysis showing that Regeneron’s R&D expenses grew by 47.9% year-to-year to $1.3 billion in 2014. Vertex had the second largest R&D outlay among the peer group, spending $855.5 million in 2014, representing a 3% decrease from 2013. R&D in 2014 was also driven by "unexpectedly sharp rises in spending from Jazz and Alnylam". Click here for more information on the report.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
